Limitations of beta-lactam therapy for infections caused by susceptible Gram-positive bacteria

Journal of Infection

Volumn 69, Issue S1, 2014, Pages S5-S9

  English, B Keith ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Eagle effect; Penicillin; Pneumococcus; Streptococcus

Indexed keywords

AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CLINDAMYCIN; MACROLIDE; PENICILLIN DERIVATIVE; PENICILLIN G; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG EFFICACY; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; GROUP A STREPTOCOCCAL INFECTION; GROUP A STREPTOCOCCAL MYOSITIS; GROUP B STREPTOCOCCAL SEPSIS; HUMAN; IN VITRO STUDY; MONOTHERAPY; MYOSITIS; NECROTIZING FASCIITIS; NONHUMAN; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; SEPSIS; SOFT TISSUE INFECTION; STREPTOCOCCUS PNEUMONIA; TOXIC SHOCK SYNDROME; ANIMAL; CLASSIFICATION; DRUG EFFECTS; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIOLOGY; MOUSE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84909993872     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2014.07.010     Document Type: Article

References (43)

1. Fleming A. On the antibacterial activity of cultures of Penicillium, with special reference to their use in the isolation of B. influenzae. Brit J Exp Path 1929, 20:226-236.
2. Chain E., Florey H.W., Gardner A.D., Heatley N.G., Jennings M.A., Orr-Ewing J., et al. Penicillin as a chemotherapeutic agent. Lancet 1940, ii:226-228.
3. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/.
4. Lewis K. Platforms for drug discovery. Nat Rev Drug Disc 2013, 12:371-387.
5. Barber M., Rozwadowska-Dowzensko M. Infection by penicillin-resistant staphylococci. Lancet 1949, 252:641-644.
6. Eagle H. Experimental approach to the problem of treatment failure with penicillin in Group A streptococcal infections in mice. Am J Med 1952, 13:389-399.
7. Moberg C.L. Rene Dubos: a harbinger of microbial resistance to antibiotics. Microb Drug Resist 1996, 2:287-297.
8. Stevens D.L., Bryant-Gibbons A.E., Bergstrom R., Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988, 158:23-28.
9. Report of the committee on infectious diseases of the American academy of pediatrics 1997, 490. Red Book. 24th ed.
10. Zimbelman J., Palmer A., Todd J. Improved outcome of clindamycin compared with beta- lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999, 18:1096-1100.
11. Report of the committee on infectious diseases of the American academy of pediatrics 2000, 553. Red Book, 580-581. 25th ed.
12. Report of the committee on infectious diseases of the American academy of pediatrics 2012, 676. Red Book. 29th ed.
13. Manual of Childhood Infections The blue book, Royal College of Paediatrics and Child Health 2011, 717-723. Oxford University Press. 3rd ed.
14. Carapetis J. Management of invasive group A streptococcal infections. J Infect 2014, 69:S63-S69.
15. Stevens D., Yan S., Bryant A.E. Penicillin-binding protein expression at different growth stages determines penicillin efficacy invitro and invivo: an explanation for the inoculum effect. J Infect Dis 1993, 167:1401-1405.
16. Stevens D.L. Streptococcal toxic shock syndrome associated with necrotizing fasciitis. Annu Rev Med 2000, 51:271-288.
17. Nau R., Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002, 15:95-110.
18. Nau R., Wellmer A., Soto A., Koch K., Schneider O., Schmidt H., et al. Rifampin reduces early mortality in Streptococcus pneumoniae meningitis. J Infect Dis 1999, 179:1557-1560.
19. Gerber J., Raivich G., Wellmer A., Noeske D.C., Kunst T., Werner A., et al. A mouse model of Streptococcus pneumoniae meningitis mimicking several features of human disease. Acta Neuropathol 2001, 101:499-508.
20. Bottcher T., Ren H., Goiny M., Gerber J., Lykkesfeldt J., Kuhnt U., et al. Clindamycin is neuroprotective in experimental Streptococcus pneumoniae meningitis compared with ceftriaxone. J Neurochem 2004, 91:1450-1460.
21. Spreer A., Lugert R., Stoltefaut V., Hoecht A., EIffert H., Nau R. Short-term rifampicin pretreatment reduces inflammation and neuronal cell death in a rabbit model of bacterial meningitis. Crit Care Med 2009, 37:2253-2258.
22. Spreer A., Gerber J., Hanssen M., Schindler S., Hermann C., Lange P., et al. Dexamethasone increases hippocampal neuronal apoptosis in a rabbit model of Escherichia coli meningitis. Pediatr Res 2006, 60:210-215.
23. Stanek R.J., Mufson M.A. A 20-year epidemiological study of pneumococcal meningitis. Clin Infect Dis 1999, 28:1265-1272.
24. Buckingham S.C., McCullers J.A., Lujan-Zilbermann, Knapp K.M., Orman K.L., English B.K. Early vancomycin therapy and adverse outcomes in children with pneumococcal meningitis. Pediatrics 2006, 117:1688-1694.
25. Bradley J.S., Byington C.L., Shah S.S., ALverson B., Carter E.R., Harrison C., et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011, 53:e25-76.
26. Buckingham S.C., Brown S.P., Joaquin V.H. Breakthrough bacteremia and meningitis during treatment with cephalsporins parenterally for pneumococcal pneumonia. J Pediatr 1998, 132:174-176.
27. Dowell S.F., Smith T., Leversedge K., Snitzer J. Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. Clin Infect Dis 1999, 29:462-463.
28. Feikin D.R., Schuchat A., Kolczak M., Barrett N.L., Harrison L.H., Lefkowitz L., et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1997-1997. Am J Public Health 2000, 90:223-229.
29. Tan T.Q., Mason E.O., Barson W.J., Wald E.R., Schutze G.E., Bradley J.S., et al. Clinical characteristics and outcome of children with pneumonia attributable to penicillin- susceptible and non-susceptible Streptococcus pneumoniae. Pediatrics 1998, 102:1369-1375.
30. English B.K., Buckingham S.C. Impact of antimicrobial resistance on therapy of bacterial pneumonia in children. Adv Exp Med Biol 2006, 58215-58315.
31. ®-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003, 36:389-395.
32. Baddour L.M., Yu V.L., Klugman K.P., et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004, 170:440-444.
33. Garcia V.E., Mensa J., Martinez J.A., et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005, 24:190-195.
34. Martin-Loeches I., Lisboa T., Rodriguez A., et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010, 36:612-620.
35. Restrepo M.I., Mortensen E.M., Waterer G.W., Wunderink R.G., Coalson J.J., Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009, 33:153-159.
36. Sligl W.I., Asadi L., Durich D.T., Tjosvold L., Marrie T.J., Majumdar S.R. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 2014, 42:420-432.
37. Karlstrom A., Boyd K.L., English B.K., McCullers J.A. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 2009, 199:1-9.
38. Karlstrom A., Heston S.M., Boyd K.L., Tuomanen E.I., McCullers J.A. Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza. J Infect Dis 2011, 204:1358-1366.
39. McCullers J.A., English B.K. Improving therapeutic strategies for secondary bacterial pneumonia following influenza. Future Microbiol 2008, 4:397-404.
40. Saiman L., Marshall B.C., Mayer-Hamblett N., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
41. Ingram K., Marker M., Meals E., Talati A.J., Spentzas T., English B.K. Azithromycin inhibits tumor necrosis factor secretion in response to both azithromycin-susceptible and azithromycin-resistant pneumococci. J Pediatr Infect Dis S 2014, 3(2):168-171. first published online April 5, 2013 http://dx.doi.org/10.1093/jpids/pit014.
42. Centers for Disease Control Prevention of perinatal group B streptococcal disease: revised guidelines from the CDC. MMWR 2010, 59(RR-10):1-32.
43. Upadhyay K., Meals E.A., English B.K., Talati A.J. Combination of ampicillin and azithromycin improved outcomes in mouse model of Group B streptococcus sepsis May 5, 2013, Abstract presentation, Pediatric Academic Societies meeting, Washington, D.C.